Latest Trials
Latest News
FAQ
Pharmaceutical Companies
Pharma Details
HUIHAN WANG
🇦🇺
Australia
Country
🇦🇺
Australia
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News
Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial
Phase 3
Recruiting
Conditions
Acute Myeloid Leukemia
Interventions
Drug: rhTPO
Drug: Decitabine
Subscribe
First Posted Date
2022-05-19
Last Posted Date
2022-05-19
Lead Sponsor
Huihan Wang
Target Recruit Count
130
Registration Number
NCT05382390
Locations
🇨🇳
ShengJing Hospital of China Medical University, Shenyang, Liaoning, China
Subscribe
Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen for Elderly Patients With Acute Myeloid Leukemia: A Phase II Single-Arm Multicenter Study
Not Applicable
Recruiting
Conditions
Acute Myeloid Leukemia
Interventions
Drug: rhTPO
Subscribe
First Posted Date
2022-02-28
Last Posted Date
2022-02-28
Lead Sponsor
Huihan Wang
Target Recruit Count
130
Registration Number
NCT05258799
Locations
🇨🇳
ShengJing Hospital of China Medical University, Shenyang, Liaoning, China
Subscribe
D-CTAG in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients
Not Applicable
Recruiting
Conditions
Acute Myeloid Leukemia
Interventions
Drug: rhTPO
Subscribe
First Posted Date
2019-11-19
Last Posted Date
2019-11-19
Lead Sponsor
Huihan Wang
Target Recruit Count
20
Registration Number
NCT04168138
Locations
🇨🇳
ShengJing Hospital of China Medical University, Shenyang, Liaoning, China
Subscribe
Prev
1
Next
© Copyright 2024. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy